NasdaqGS - Delayed Quote USD

Regeneron Pharmaceuticals, Inc. (REGN)

890.68 -15.86 (-1.75%)
At close: April 25 at 4:00 PM EDT
889.75 -0.93 (-0.10%)
After hours: April 25 at 7:15 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
13,117,200.00
13,117,200.00
12,172,900.00
16,071,700.00
8,497,100.00
Cost of Revenue
1,815,800.00
1,815,800.00
1,560,400.00
2,437,500.00
1,119,900.00
Gross Profit
11,301,400.00
11,301,400.00
10,612,500.00
13,634,200.00
7,377,200.00
Operating Expense
7,068,200.00
7,068,200.00
5,618,500.00
4,639,400.00
3,800,600.00
Operating Income
4,233,200.00
4,233,200.00
4,994,000.00
8,994,800.00
3,576,600.00
Net Non Operating Interest Income Expense
422,900.00
422,900.00
100,700.00
-11,500.00
-56,900.00
Other Income Expense
-456,800.00
-456,800.00
-235,900.00
342,500.00
290,700.00
Pretax Income
4,199,300.00
4,199,300.00
4,858,800.00
9,325,800.00
3,810,400.00
Tax Provision
245,700.00
245,700.00
520,400.00
1,250,500.00
297,200.00
Net Income Common Stockholders
3,953,600.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Diluted NI Available to Com Stockholders
3,953,600.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Basic EPS
37.05
--
40.51
76.40
32.65
Diluted EPS
34.77
--
38.22
71.97
30.52
Basic Average Shares
106,700.00
--
107,100.00
105,700.00
107,600.00
Diluted Average Shares
113,700.00
--
113,500.00
112,200.00
115,100.00
Total Operating Income as Reported
4,047,100.00
4,047,100.00
4,738,900.00
8,946,800.00
3,576,600.00
Total Expenses
8,884,000.00
8,884,000.00
7,178,900.00
7,076,900.00
4,920,500.00
Net Income from Continuing & Discontinued Operation
3,953,600.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Normalized Income
4,364,628.80
4,364,628.80
4,556,917.10
7,782,159.00
3,513,200.00
Interest Income
495,900.00
495,900.00
160,100.00
45,800.00
--
Interest Expense
73,000.00
73,000.00
59,400.00
57,300.00
56,900.00
Net Interest Income
422,900.00
422,900.00
100,700.00
-11,500.00
-56,900.00
EBIT
4,272,300.00
4,272,300.00
4,918,200.00
9,383,100.00
3,867,300.00
EBITDA
4,693,300.00
4,693,300.00
5,259,600.00
9,669,300.00
4,103,200.00
Reconciled Cost of Revenue
1,815,800.00
1,815,800.00
1,560,400.00
2,437,500.00
1,119,900.00
Reconciled Depreciation
421,000.00
421,000.00
341,400.00
286,200.00
235,900.00
Net Income from Continuing Operation Net Minority Interest
3,953,600.00
3,953,600.00
4,338,400.00
8,075,300.00
3,513,200.00
Total Unusual Items Excluding Goodwill
-436,800.00
-436,800.00
-244,700.00
338,500.00
--
Total Unusual Items
-436,800.00
-436,800.00
-244,700.00
338,500.00
--
Normalized EBITDA
5,130,100.00
5,130,100.00
5,504,300.00
9,330,800.00
4,103,200.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-25,771.20
-25,771.20
-26,182.90
45,359.00
--
12/31/2020 - 4/2/1991

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VRTX Vertex Pharmaceuticals Incorporated
397.70
-0.76%
 
BNTX BioNTech SE
86.71
-1.57%
 
ALNY Alnylam Pharmaceuticals, Inc.
143.71
-0.06%
 
MDGL Madrigal Pharmaceuticals, Inc.
194.38
-5.02%
 
BMRN BioMarin Pharmaceutical Inc.
82.17
-9.90%
 
MRNA Moderna, Inc.
106.18
-2.45%
 
CRSP CRISPR Therapeutics AG
53.73
-3.45%
 
INCY Incyte Corporation
51.18
-1.08%
 
NTLA Intellia Therapeutics, Inc.
20.02
-5.43%
 
NVO Novo Nordisk A/S
125.79
-0.29%